BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31018208)

  • 1. Placenta-Specific 8 Is Overexpressed and Regulates Cell Proliferation in Low-Grade Human Pancreatic Neuroendocrine Tumors.
    Tatura M; Schmidt H; Haijat M; Stark M; Rinke A; Diels R; Lawlor RT; Scarpa A; Schrader J; Hackert T; Schimmack S; Gress TM; Buchholz M
    Neuroendocrinology; 2020; 110(1-2):23-34. PubMed ID: 31018208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulatory Pathways.
    Kaistha BP; Lorenz H; Schmidt H; Sipos B; Pawlak M; Gierke B; Kreider R; Lankat-Buttgereit B; Sauer M; Fiedler L; Krattenmacher A; Geisel B; Kraus JM; Frese KK; Kelkenberg S; Giese NA; Kestler HA; Gress TM; Buchholz M
    Cancer Res; 2016 Jan; 76(1):96-107. PubMed ID: 26669866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization.
    Capodanno Y; Chen Y; Schrader J; Tomosugi M; Sumi S; Yokoyama A; Hiraoka N; Ohki R
    Neoplasia; 2021 Sep; 23(9):979-992. PubMed ID: 34352404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors.
    Yamauchi Y; Kodama Y; Shiokawa M; Kakiuchi N; Marui S; Kuwada T; Sogabe Y; Tomono T; Mima A; Morita T; Matsumori T; Ueda T; Tsuda M; Nishikawa Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Masuda A; Tatsuoka H; Yabe D; Minamiguchi S; Masui T; Inagaki N; Uemoto S; Chiba T; Seno H
    Cancer Res; 2020 Sep; 80(17):3620-3630. PubMed ID: 32591410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
    Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
    Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
    Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
    Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients.
    Speisky D; Duces A; Bièche I; Rebours V; Hammel P; Sauvanet A; Richard S; Bedossa P; Vidaud M; Murat A; Niccoli P; Scoazec JY; Ruszniewski P; Couvelard A;
    Clin Cancer Res; 2012 May; 18(10):2838-49. PubMed ID: 22461457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs.
    Ueda H; Akiyama Y; Shimada S; Mogushi K; Serizawa M; Matsumura S; Mitsunori Y; Aihara A; Ban D; Ochiai T; Kudo A; Tanabe M; Tanaka S
    Endocr Relat Cancer; 2018 Jun; 25(6):619-631. PubMed ID: 29599123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel KLF4/PLAC8 signaling pathway regulates lung cancer growth.
    Jia Y; Ying X; Zhou J; Chen Y; Luo X; Xie S; Wang QC; Hu W; Wang L
    Cell Death Dis; 2018 May; 9(6):603. PubMed ID: 29789534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression.
    Xu J; Ye Z; Zhuo Q; Gao H; Qin Y; Lou X; Zhang W; Wang F; Wang Y; Jing D; Fan G; Zhang Y; Chen X; Chen J; Xu X; Yu X; Ji S
    Cancer Res; 2023 Jul; 83(13):2226-2247. PubMed ID: 36939378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism.
    Wiedmer T; Blank A; Pantasis S; Normand L; Bill R; Krebs P; Tschan MP; Marinoni I; Perren A
    Mol Cancer Ther; 2017 Nov; 16(11):2502-2515. PubMed ID: 28729403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
    Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
    Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
    Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM).
    Noë M; Hackeng WM; de Leng WWJ; Vergeer M; Vleggaar FP; Morsink FHM; Wood LD; Hruban RH; Offerhaus GJA; Brosens LAA
    Am J Surg Pathol; 2019 Sep; 43(9):1297-1302. PubMed ID: 31261289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors.
    Wu Y; Tedesco L; Lucia K; Schlitter AM; Garcia JM; Esposito I; Auernhammer CJ; Theodoropoulou M; Arzt E; Renner U; Stalla GK
    Oncotarget; 2016 Sep; 7(36):57878-57893. PubMed ID: 27506944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.
    Wen J; Chen J; Liu D; Xu X; Fan M; Zhang Z
    Neuroendocrinology; 2020; 110(5):364-376. PubMed ID: 31357196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
    Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
    Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors.
    Cives M; Partelli S; Palmirotta R; Lovero D; Mandriani B; Quaresmini D; Pelle' E; Andreasi V; Castelli P; Strosberg J; Zamboni G; Falconi M; Silvestris F
    Sci Rep; 2019 Dec; 9(1):18614. PubMed ID: 31819132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.